TapewireFind a company

person · Reporting owner

KASINGER JAMES R.

Disclosed activity across 1 company

Tapewire entity
42394
SEC CIK
0001708172

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CRISPR Therapeutics AGCRSP · Entity 3852General Counsel and SecretaryOctober 06, 2026October 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CRISPR Therapeutics AG

Report date October 06, 2026 · Filed October 08, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeDirect94,784 Ending reported balance After 2026-10-06 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-10-06 · Exercise / conversion · Acquired 1,990 · Balance 96,774

Row 2 · 2026-10-06 · Sale · Disposed 1,990 · Balance 94,784

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.62 · Expires 2027-05-31Direct81,242 Reported balance After 2026-10-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-10-06 · Exercise / conversion · Disposed 1,990 · Balance 81,242

F3: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 11, 2024 Filed Mar 12, 2024 21:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 2,250 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-030190 · ownership.xml · derivative · entry 6

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,250

Underlying: Common Shares · 2,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F4 · derivative.exercise_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.

F4 · derivative.expiration_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.

Read SEC document
March 11, 2024 Filed Mar 12, 2024 21:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 2,250 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-030190 · ownership.xml · nonDerivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,320

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Read SEC document
March 11, 2024 Filed Mar 12, 2024 21:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 SaleCommon Shares 2,801 $78.26 $219,206.26
Disclosure

SEC source: 0000950170-24-030190 · ownership.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,070

F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
March 10, 2024 Filed Mar 12, 2024 21:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 5,500 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-030190 · ownership.xml · derivative · entry 5

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,500

Underlying: Common Shares · 5,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.

F3 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.

Read SEC document
March 10, 2024 Filed Mar 12, 2024 21:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 5,500 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-030190 · ownership.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,871

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Read SEC document
February 20, 2024 Filed Feb 21, 2024 22:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 SaleCommon Shares 1,913 $79.67 $152,408.71
Disclosure

SEC source: 0000950170-24-018175 · ownership.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,371

F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
February 18, 2024 Filed Feb 21, 2024 22:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 3,825 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-018175 · ownership.xml · derivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,650

Underlying: Common Shares · 3,825 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F4 · derivative.exercise_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.

F4 · derivative.expiration_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.

Read SEC document
February 18, 2024 Filed Feb 21, 2024 22:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 3,825 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-018175 · ownership.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,284

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F2 · balance_after: Includes 615 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.

Read SEC document
October 13, 2023 Filed Oct 17, 2023 21:48 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantRestricted Stock Units · Derivative 6,340 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-053817 · ownership.xml · derivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,340

Underlying: Common Shares · 6,340 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3 · derivative.exercise_date: This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.

F3 · derivative.expiration_date: This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.

Read SEC document
October 13, 2023 Filed Oct 17, 2023 21:48 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantStock Option (Right to Buy) · Derivative 16,667 $0.00 Strike: $44.31 $0.00
Disclosure

SEC source: 0000950170-23-053817 · ownership.xml · derivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,667

Underlying: Common Shares · 16,667 shares

Expires 2033-10-13

F1 · derivative.exercise_date: This option was granted on October 13, 2023 with respect to 16,667 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023.

Read SEC document
March 13, 2023 Filed Mar 14, 2023 21:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Tax withholdingCommon Shares 1,022 $43.22 $44,170.84
Disclosure

SEC source: 0001209191-23-018564 · doc4.xml · nonDerivative · entry 4

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,844

F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
March 13, 2023 Filed Mar 14, 2023 21:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Tax withholdingCommon Shares 1,283 $43.22 $55,451.26
Disclosure

SEC source: 0001209191-23-018564 · doc4.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,616

F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
March 11, 2023 Filed Mar 14, 2023 21:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 2,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-018564 · doc4.xml · derivative · entry 8

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,500

Underlying: Common Shares · 2,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F6 · derivative.exercise_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.

F6 · derivative.expiration_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.

Read SEC document
March 11, 2023 Filed Mar 14, 2023 21:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 2,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-018564 · doc4.xml · nonDerivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,866

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Read SEC document
March 10, 2023 Filed Mar 14, 2023 21:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantRestricted Stock Units · Derivative 22,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-018564 · doc4.xml · derivative · entry 7

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Shares · 22,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F5 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.

F5 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.

Read SEC document
March 10, 2023 Filed Mar 14, 2023 21:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $43.22 $0.00
Disclosure

SEC source: 0001209191-23-018564 · doc4.xml · derivative · entry 6

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Shares · 40,000 shares

Expires 2033-03-10

F4 · derivative.exercise_date: This option was granted on March 10, 2023 with respect to 40,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2023.

Read SEC document
March 10, 2023 Filed Mar 14, 2023 21:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 2,833 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-018564 · doc4.xml · derivative · entry 5

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 2,833 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023.

F3 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023.

Read SEC document
March 10, 2023 Filed Mar 14, 2023 21:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 2,833 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-018564 · doc4.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,899

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Read SEC document
February 21, 2023 Filed Feb 22, 2023 22:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Tax withholdingCommon Shares 1,950 $48.26 $94,107.00
Disclosure

SEC source: 0001209191-23-011777 · doc4.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,066

F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
February 18, 2023 Filed Feb 22, 2023 22:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 3,825 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-011777 · doc4.xml · derivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,475

Underlying: Common Shares · 3,825 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3 · derivative.exercise_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.

F3 · derivative.expiration_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.

Read SEC document
February 18, 2023 Filed Feb 22, 2023 22:35 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 3,825 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-011777 · doc4.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,016

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Read SEC document
December 05, 2022 Filed Dec 6, 2022 22:47 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Tax withholdingCommon Shares 3,234 $52.26 $169,008.84
Disclosure

SEC source: 0001209191-22-060090 · doc4.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,191

F4 · kind: On December 3, 2019, the reporting person was granted 20,000 restricted stock units. On December 3, 2022, 6,667 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
December 03, 2022 Filed Dec 6, 2022 22:47 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 6,667 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-060090 · doc4.xml · derivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 6,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · derivative.exercise_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022.

F1 · derivative.expiration_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022.

Read SEC document
December 03, 2022 Filed Dec 6, 2022 22:47 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 6,667 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-060090 · doc4.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,425

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3 · balance_after: Includes 329 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.

Read SEC document
October 07, 2022 Filed Oct 12, 2022 21:40 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantStock Option (Right to Buy) · Derivative 14,000 $0.00 Strike: $61.65 $0.00
Disclosure

SEC source: 0001209191-22-053494 · doc4.xml · derivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Shares · 14,000 shares

Expires 2032-10-07

F1 · derivative.exercise_date: This option was granted on October 7, 2022 with respect to 14,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 7, 2022.

Read SEC document
August 16, 2022 Filed Aug 18, 2022 21:33 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantRestricted Stock Units · Derivative 20,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-046707 · doc4.xml · derivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Shares · 20,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F2 · derivative.exercise_date: The restricted stock units shall vest in full on February 16, 2025, subject to continued service to the Company or any of its subsidiaries.

F2 · derivative.expiration_date: The restricted stock units shall vest in full on February 16, 2025, subject to continued service to the Company or any of its subsidiaries.

Read SEC document
March 14, 2022 Filed Mar 14, 2022 22:01 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Tax withholdingCommon Shares 1,039 $61.08 $63,462.12
Disclosure

SEC source: 0001209191-22-018609 · doc4.xml · nonDerivative · entry 4

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,429

F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
March 11, 2022 Filed Mar 14, 2022 22:01 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 2,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-018609 · doc4.xml · derivative · entry 6

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,750

Underlying: Common Shares · 2,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F5 · derivative.exercise_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.

F5 · derivative.expiration_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.

Read SEC document
March 11, 2022 Filed Mar 14, 2022 22:01 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 2,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-018609 · doc4.xml · nonDerivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,468

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Read SEC document
March 11, 2022 Filed Mar 14, 2022 22:01 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Tax withholdingCommon Shares 1,321 $62.56 $82,641.76
Disclosure

SEC source: 0001209191-22-018609 · doc4.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,218

F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
March 10, 2022 Filed Mar 14, 2022 22:01 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 2,834 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-018609 · doc4.xml · derivative · entry 5

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,833

Underlying: Common Shares · 2,834 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F4 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023.

F4 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023.

Read SEC document
March 10, 2022 Filed Mar 14, 2022 22:01 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 2,834 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-018609 · doc4.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,539

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F2 · balance_after: Includes 163 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.

Read SEC document
February 18, 2022 Filed Feb 22, 2022 22:40 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantRestricted Stock Units · Derivative 15,300 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-011836 · doc4.xml · derivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,300

Underlying: Common Shares · 15,300 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3 · derivative.exercise_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.

F3 · derivative.expiration_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.

Read SEC document
February 18, 2022 Filed Feb 22, 2022 22:40 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantStock Option (Right to Buy) · Derivative 34,200 $0.00 Strike: $58.29 $0.00
Disclosure

SEC source: 0001209191-22-011836 · doc4.xml · derivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,200

Underlying: Common Shares · 34,200 shares

Expires 2032-02-18

F1 · derivative.exercise_date: This option was granted on February 18, 2022 with respect to 34,200 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of March 18, 2022.

Read SEC document
December 06, 2021 Filed Dec 8, 2021 01:00 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Tax withholdingCommon Shares 6,303 $69.17 $435,978.51
Disclosure

SEC source: 0001209191-21-068453 · doc4.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,542

F3 · kind: On December 3, 2019, the reporting person was granted 20,000 restricted stock units. On December 3, 2021, 13,333 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
December 03, 2021 Filed Dec 8, 2021 01:00 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionRestricted Stock Units · Derivative 13,333 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-068453 · doc4.xml · derivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,667

Underlying: Common Shares · 13,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · derivative.exercise_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022.

F1 · derivative.expiration_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022.

Read SEC document
December 03, 2021 Filed Dec 8, 2021 01:00 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 13,333 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-068453 · doc4.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,845

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Read SEC document
December 02, 2021 Filed Dec 4, 2021 01:00 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionStock Option (Right to Buy) · Derivative 7,342 $0.00 Strike: $13.62 $0.00
Disclosure

SEC source: 0001209191-21-068014 · doc4.xml · derivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,632

Underlying: Common Shares · 7,342 shares

Expires 2027-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% vested on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.

Read SEC document
December 02, 2021 Filed Dec 4, 2021 01:00 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 7,342 $13.62 $99,998.04
Disclosure

SEC source: 0001209191-21-068014 · doc4.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,512

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 15, 2021 Filed Oct 19, 2021 00:00 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantStock Option (Right to Buy) · Derivative 10,800 $0.00 Strike: $97.00 $0.00
Disclosure

SEC source: 0001209191-21-060778 · doc4.xml · derivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,800

Underlying: Common Shares · 10,800 shares

Expires 2031-10-15

F1 · derivative.exercise_date: This option was granted on October 15, 2021 with respect to 10,800 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 15, 2021.

Read SEC document
September 13, 2021 Filed Sep 15, 2021 01:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Tax withholdingCommon Shares 4,741 $117.86 $558,774.26
Disclosure

SEC source: 0001209191-21-056093 · doc4.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,170

F3 · kind: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
September 10, 2021 Filed Sep 15, 2021 01:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Disposition to issuerRestricted Stock Units · Derivative 10,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-056093 · doc4.xml · derivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 10,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F1 · derivative.exercise_date: The restricted stock unit award was granted on September 10, 2019 with respect to 10,000 Common Shares, with all shares vesting on September 10, 2021.

F1 · derivative.expiration_date: The restricted stock unit award was granted on September 10, 2019 with respect to 10,000 Common Shares, with all shares vesting on September 10, 2021.

Read SEC document
September 10, 2021 Filed Sep 15, 2021 01:45 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 10,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-056093 · doc4.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,911

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The restricted stock unit award was granted on September 10, 2019 with respect to 10,000 Common Shares, with all shares vesting on September 10, 2021.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Read SEC document
March 11, 2021 Filed Mar 12, 2021 22:43 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantRestricted Stock Units · Derivative 9,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-020253 · doc4.xml · derivative · entry 4

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Shares · 9,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F5 · derivative.exercise_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.

F5 · derivative.expiration_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.

Read SEC document
March 11, 2021 Filed Mar 12, 2021 22:43 UTC CRISPR Therapeutics AG CRSP · Entity 3852 GrantStock Option (Right to Buy) · Derivative 25,360 $0.00 Strike: $133.88 $0.00
Disclosure

SEC source: 0001209191-21-020253 · doc4.xml · derivative · entry 3

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,360

Underlying: Common Shares · 25,360 shares

Expires 2031-03-11

F4 · derivative.exercise_date: This option was granted on March 11, 2021 with respect to 25,360 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 11, 2021.

Read SEC document
March 10, 2021 Filed Mar 12, 2021 22:43 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Tax withholdingCommon Shares 1,353 $124.15 $167,974.95
Disclosure

SEC source: 0001209191-21-020253 · doc4.xml · nonDerivative · entry 2

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,911

F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Read SEC document
March 10, 2021 Filed Mar 12, 2021 22:43 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionCommon Shares 2,833 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-020253 · doc4.xml · nonDerivative · entry 1

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,264

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Read SEC document
January 19, 2021 Filed Jan 20, 2021 23:05 UTC CRISPR Therapeutics AG CRSP · Entity 3852 Exercise / conversionStock Option (right to buy) · Derivative 27,500 $0.00 Strike: $51.49 $0.00
Disclosure

SEC source: 0001209191-21-004452 · doc4.xml · derivative · entry 7

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Shares · 27,500 shares

Expires 2028-03-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: This option was granted on March 7, 2018 with respect to 40,000 Common Shares and vests in 48 equal monthly installments.

Read SEC document
January 19, 2021 Filed Jan 20, 2021 23:05 UTC CRISPR Therapeutics AG CRSP · Entity 3852 SaleCommon Shares 2,100 $207.61 $435,981.00
Disclosure

SEC source: 0001209191-21-004452 · doc4.xml · nonDerivative · entry 6

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,431

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $207.39 to $208.1050, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
January 19, 2021 Filed Jan 20, 2021 23:05 UTC CRISPR Therapeutics AG CRSP · Entity 3852 SaleCommon Shares 1,800 $206.05 $370,890.00
Disclosure

SEC source: 0001209191-21-004452 · doc4.xml · nonDerivative · entry 5

KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,531

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.00 to $206.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.